Congress Materials – American Society of Clinical Psychopharmacology (ASCP 2026)
2026 American Society of Clinical Psychopharmacology Annual Meeting | May 26-29 | Miami, FL
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Adjunctive Lumateperone 42 mg Treatment in Major Depressive Disorder: Efficacy Across Patient-Reported Depression Symptoms
Suresh Durgam, Willie R. Earley, Susan G. Kozauer, Changzheng Chen, Alvin B. Oung, Rakesh Jain
Association of Major Depressive Disorder With Insomnia Symptoms With Healthcare Resource Use and Cardiovascular and Metabolic Conditions – Analysis of the National Health & Nutrition Examination Survey
Hrishikesh Kale, Zhiwen Liu, Karen Johnston, Guo Li, Carmela Benson, Zhiheng Zhang
Efficacy of Lumateperone 42 mg for the Treatment of Major Depressive Disorder: Analysis of Demographic and Clinical Subgroups in a Phase 3 Randomized Placebo-Controlled Trial
Suresh Durgam; Willie R. Earley; Dennis Sholler; Hassan Lakkis; Roger S. McIntyre; Maurizio Fava
Esketamine Nasal Spray for Relapse Prevention in Patients With Treatment-Resistant Depression: A Post Hoc Analysis of Predictors of Relapse in Placebo-Treated Patients in SUSTAIN-1
Richard Shelton, Ibrahim Turkoz, Dong-Jing Fu, Mai Himedan, Lisa Lim, Oliver Lopena, Alexis Davis, Manish Patel, Toya Bowles
First Onset and Duration of Treatment-Emergent Adverse Events in Patients With Major Depressive Disorder Treated With Adjunctive Lumateperone 42 mg: A Pooled Analysis of 2 Randomized Placebo-Controlled Trials
Willie R. Earley; Suresh Durgam; Susan G. Kozauer; Changzheng Chen; Margaret Martin; Andrew J. Cutler; Stephen M. Stahl
Impact of Seltorexant on Cognitive Performance of Adults with Major Depressive Disorder with Insomnia Symptoms
Amy Wegener, Ryan Kelly, Yun Zhang, Randall L. Morrison, Yanina Flossbach, Sofie Mesens, Wayne C. Drevets, Gahan Pandina
Improvement of Predominant Negative Symptoms in Patients With Schizophrenia on Paliperidone Palmitate 6-month Long-Acting Injectable: Post-Hoc Analysis Over 3 Years
Jordy Mehawej, José Antunes, Ibrahim Turkoz, Leslie Killion, R. Karl Knight, Christoph U. Correll
Lumateperone 42 mg in Major Depressive Disorder: Demographic and Clinical Subgroups Efficacy Analysis in a Phase 3 Randomized Placebo-Controlled Trial
Raffaele Migliore; Willie R. Earley; Suresh Durgam; Yifan Mo; Joanna Armas-Datorre; Susan G. Kornstein
Lumateperone Versus Other Adjunctive Atypical Antipsychotics for Major Depressive Disorder: A Network Meta-Analysis of Comparative Efficacy and Safety
Andrew J. Cutler; Anaïs Lemyre; Qiaoyi Zhang; Carol Mao; Todor I. Totev; Marjolaine Gauthier-Loiselle; Yujie Wu; Jingyi Liu; Mahmoud Hashim; Madhav Namjoshi; John J. Sheehan; Dominic Pilon; Patrick Lefebvre; Antoine El Khoury; Leslie Citrome
Metabolic Profile of Adjunctive Lumateperone 42 mg in Major Depressive Disorder: A Pooled Analysis of 2 Randomized, Placebo-Controlled Trials
Willie R. Earley; Suresh Durgam; Susan G. Kozauer; Samar Madi; Michael Smith; Craig Chepke
Metabolic Profiles of Participants With Major Depressive Disorder With Insomnia Symptoms in a Phase 3 Trial of Seltorexant Versus Quetiapine Extended Release as Adjunctive Therapy
Gahan Pandina, Sofie Mesens, Lu Xia, Ewa Wajs, Joseph M. Trombello, Ryan Kelly, Yun Zhang, Haiyan Xu, Yanina Flossbach, Carla M. Canuso, Wayne C. Drevets
Perspectives of Nurse Practitioners and Physician Associates on Presenting Long-Acting Injectables to Adults with Schizophrenia: A Delphi Panel Study
Daphne Weeks, Sonny Cline, Kody Green, Jason Gray, Karen Johnston, Laura Morrison, Lilian Diaz, Neema Lema, Dominic Pilon, Leslie Citrome
Remission With Lumateperone 42 mg Adjunctive to Antidepressant Therapy in Patients With Major Depressive Disorder: Analysis of Short-Term and Long-Term Trials
Raffaele Migliore; Suresh Durgam; Willie R. Earley; Changzheng Chen; Eleni Mastromihalis; Michael E. Thase
Schizophrenia-Related Hospitalization History Before Long-Acting Injectable Antipsychotic Initiation and Its Association with Subsequent Adherence and Hospitalizations among Dual-Eligibles: The CRITICAL PERIOD Study
Pengxiang Li, Zhi Geng, Brahim Bookhart, Carmela Benson, Jalpa Doshi
Seltorexant Versus Quetiapine Extended Release as Adjunctive Treatment in Major Depressive Disorder With Insomnia Symptoms: Phase 3 Trial
Yanina Flossbach, Sofie Mesens, Gahan Pandina, Ryan Kelly, Yun Zhang, Haiyan Xu, Lu Xia, Carla M. Canuso, Wayne C. Drevets
Seltorexant, Adjunctive to Antidepressants, in Adults With Major Depressive Disorder With Insomnia Symptoms: Phase 3 Studies
Gahan Pandina, Michael E. Thase, Andrew D. Krystal, Ewa Wajs, Joseph M. Trombello, Katherine Bevans, Ryan Kelly, Yun Zhang, Haiyan Xu, Sandra Ruschel, Yanina Flossbach, Sofie Mesens, Lu Xia, Thomas Laughren, Wayne C. Drevets
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.